Preoperative Gemcitabine/Nab‐Paclitaxel With Concurrent Radiation Therapy for Borderline Resectable Pancreatic Cancer: A Comparative Analysis With Preoperative Chemoradiation Therapy Using Gemcitabine Alone

Documenti analoghi

• Efficacy and Safety of Combination Therapy With Immune Checkpoint Inhibitors and Chemotherapy With Gemcitabine and Nab‐Paclitaxel in Pancreatic Cancer: A Systematic Review
  di: Hanye Sohrabi, et al.
  Pubblicazione: (2026)
• Prognostic impact of aberrant right hepatic artery involvement in patients with pancreatic cancer: A multicenter retrospective cohort study
  di: Hiroki Ueda, et al.
  Pubblicazione: (2024)
• Clinical Effectiveness of Tislelizumab With Gemcitabine/Cisplatin Versus Gemcitabine/Cisplatin Alone as Adjuvant Therapy for High‐Risk Muscle‐Invasive Urothelial Carcinoma: A Real‐World Study
  di: Yanjun Wang, et al.
  Pubblicazione: (2025)
• Pembrolizumab Therapy Leading to Complete Remission for Recurrence of Pulmonary Metastases after their Resection and Radical Cystectomy following Gemcitabine and Cisplatin Therapy
  di: Kyohei Ishida, et al.
  Pubblicazione: (2024)
• Comparison of Nanoliposomal Irinotecan Plus Fluorouracil/Leucovorin and S‐1, Irinotecan, and Oxaliplatin as Second‐Line Chemotherapy After Gemcitabine Plus Nab‐Paclitaxel for Unresectable Pancreatic Cancer
  di: Masahiro Itonaga, et al.
  Pubblicazione: (2026)